139 related articles for article (PubMed ID: 11952508)
1. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.
Sezer S; Ozdemir FN; Yakupoglu U; Arat Z; Turan M; Haberal M
Artif Organs; 2002 Apr; 26(4):366-70. PubMed ID: 11952508
[TBL] [Abstract][Full Text] [Related]
2. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
Tarng DC; Huang TP
Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
[TBL] [Abstract][Full Text] [Related]
3. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
5. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
Tarng DC; Huang TP; Chen TW; Yang WC
Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
[TBL] [Abstract][Full Text] [Related]
7. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
8. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
Tarng DC; Hung SC; Huang TP
J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
[TBL] [Abstract][Full Text] [Related]
11. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
13. The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia.
Kang DW; Ahn CY; Ryu BK; Shin BC; Chung JH; Kim HL
Kidney Res Clin Pract; 2012 Mar; 31(1):48-53. PubMed ID: 26889408
[TBL] [Abstract][Full Text] [Related]
14. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
16. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels.
Chen WT; Lin YF; Yu FC; Kao WY; Huang WH; Yan HC
Am J Kidney Dis; 2003 Jul; 42(1):158-66. PubMed ID: 12830468
[TBL] [Abstract][Full Text] [Related]
17. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
19. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease.
Nand N; Deshmukh AR; Mittal R
J Assoc Physicians India; 2017 Jul; 65(7):32-36. PubMed ID: 28792166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]